Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.

@article{Xu2009PopulationPO,
  title={Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.},
  author={Zhenhua Xu and Thuy Vu and Howard D Lee and Chuanpu Hu and Jie Ling and Hong Yan and Daniel Baker and Anna M Beutler and Charles Pendley and Carrie L Wagner and Hugh M. Davis and Honghui Zhou},
  journal={Journal of clinical pharmacology},
  year={2009},
  volume={49 9},
  pages={1056-70}
}
The population pharmacokinetics of subcutaneously administered golimumab (50 mg or 100 mg every 4 weeks) were characterized in patients with active psoriatic arthritis (PsA) in GO-REVEAL, a randomized, double-blind, placebo-controlled, phase 3 study. A total of 2029 serum golimumab concentrations from 337 patients were analyzed using NONMEM. A 1-compartment pharmacokinetic model with first-order absorption and elimination was chosen to describe the observed concentration-time data. For a… CONTINUE READING